Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Cancer Research UK opens olaparib-temozolomide combination Phase I trial in glioblastoma

Cancer Research UK opens olaparib-temozolomide combination Phase I trial in glioblastoma

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

First report of alternative lengthening of telomeres in human cancer subtypes

First report of alternative lengthening of telomeres in human cancer subtypes

Valproic acid may increase survival for brain tumor patients

Valproic acid may increase survival for brain tumor patients

New imaging device enables scientists to see tumor cells traveling in the brain

New imaging device enables scientists to see tumor cells traveling in the brain

MDxHealth first half 2011 commercial revenues increase 19%

MDxHealth first half 2011 commercial revenues increase 19%

MicroRNA biomarkers provide guidance to develop specific gene therapies for glioblastoma

MicroRNA biomarkers provide guidance to develop specific gene therapies for glioblastoma

Wistar Institute, Graham Cancer Center enter research collaboration

Wistar Institute, Graham Cancer Center enter research collaboration

YM BioSciences reports preclinical results of CYT387 in multiple myeloma

YM BioSciences reports preclinical results of CYT387 in multiple myeloma

ImmunoCellular receives new patent for ICT-69 to treat multiple myeloma, ovarian cancer

ImmunoCellular receives new patent for ICT-69 to treat multiple myeloma, ovarian cancer

Celldex second quarter net loss increases to $10.2 million

Celldex second quarter net loss increases to $10.2 million

FDA grants Orphan Drug Designation for Diffusion's TSC to treat glioblastoma multiforme

FDA grants Orphan Drug Designation for Diffusion's TSC to treat glioblastoma multiforme

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Researchers examine benefits of hyperbaric oxygen in treatment of aggressive brain cancer

Researchers examine benefits of hyperbaric oxygen in treatment of aggressive brain cancer

Advancements in use of zinc finger nucleases to produce genetically modified pigs

Advancements in use of zinc finger nucleases to produce genetically modified pigs

UCI study sheds light on how transplantation alleviates side effects of radiotherapy

UCI study sheds light on how transplantation alleviates side effects of radiotherapy

Progesterone could fight against neuroblastoma

Progesterone could fight against neuroblastoma

Indirubin might help treat glioblastoma

Indirubin might help treat glioblastoma

Research targets malignant glioma stem cells

Research targets malignant glioma stem cells

Charité-Universitätsmedizin Berlin establishes MagForce NanoTherm therapy center for treatment of tumors

Charité-Universitätsmedizin Berlin establishes MagForce NanoTherm therapy center for treatment of tumors

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.